Adjuvant targeted therapy for resected NSCLC: to be or not to be?

Ting Ye^{1

2}, Haiquan Chen^{1

2}

Affiliations

¹ Department of Thoracic Surgery, Shanghai Cancer Center, Fudan University, Shanghai 200032, China.
² Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.

Editorial

Ting Ye et al. J Thorac Dis. 2018 Sep.

. 2018 Sep;10(Suppl 26):S3297-S3299.

doi: 10.21037/jtd.2018.07.111.

Ting Ye^{1

2}, Haiquan Chen^{1

2}

¹ Department of Thoracic Surgery, Shanghai Cancer Center, Fudan University, Shanghai 200032, China.
² Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Adjuvant TKIs: still an optimal choice.
Liu SY, Wu YL. Liu SY, et al. J Thorac Dis. 2018 Dec;10(12):E812-E814. doi: 10.21037/jtd.2018.11.67. J Thorac Dis. 2018. PMID: 30746261 Free PMC article. No abstract available.

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yan HH, Yang XN, Zhou Q, Wu YL; ADJUVANT investigators. Zhong WZ, et al. Lancet Oncol. 2018 Jan;19(1):139-148. doi: 10.1016/S1470-2045(17)30729-5. Epub 2017 Nov 21. Lancet Oncol. 2018. PMID: 29174310 Clinical Trial.

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30. 10.3322/caac.21166 - DOI - PubMed
1. Ponn RB, Lo Cicero J III, Daly BDT. Surgical treatment of non-small cell lung cancer. In: Shields TW, Lo Cicero J III, Ponn RB, et al., editors. General Thoracic Surgery (ed6). Philadelphia, PA: Lippincott Williams & Wilkins, 2005:1548-87.
1. Gloeckler Ries LA, Reichman ME, Lewis DR, et al. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2003;8:541-52. 10.1634/theoncologist.8-6-541 - DOI - PubMed
1. Bordoni R. Consensus conference: multimodality management of early- and intermediate-stage non-small cell lung cancer. Oncologist 2008;13:945-53. 10.1634/theoncologist.2008-0062 - DOI - PubMed
1. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9. 10.1200/JCO.2007.13.9030 - DOI - PubMed